Citius Pharmaceuticals’ (CTXR) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $9.00 price target on the stock. Separately, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a report […]
D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $9.00 price target on the stock. Separately, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a report […]
